secwatch.observer — SEC 8-K summary
======================================

Issuer:     Nkarta, Inc. (NKTX)
CIK:        0001787400
Form:       8-K
Filed at:   2021-11-10T23:59:59+00:00
Accession:  0001564590-21-056198
Event type: earnings
Sentiment:  neutral
Materiality: 0.60
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Nkarta reports Q3 net loss of $22.4M; NKX101 data pushed to 1H 2022
-------------------------------------------------------------------

- Net loss of $22.4M ($0.68 per share); R&D expense $16.6M, G&A $5.8M.
- Cash, equivalents, restricted cash and short-term investments totaled $259.8M; runway into at least 2H 2023.
- NKX101 Phase 1 data for AML/MDS expected in 1H 2022 (updated from prior guidance).
- First patients dosed in NKX019 Phase 1 for B cell malignancies; initial data expected in 2022.
- Leased new 88,000 sq ft manufacturing facility and HQ to support pivotal trials and commercial launch.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1787400/000156459021056198/0001564590-21-056198-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1787400/000156459021056198/nktx-8k_20211110.htm
  HTML page:      https://secwatch.observer/filing/0001564590-21-056198

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer